208 related articles for article (PubMed ID: 32726929)
21. Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression.
Chen CY; Chen YY; Chen JJW; Chen KY; Ho CC; Shih JY; Chang YL; Yu CJ; Yang PC
Oncotarget; 2017 Sep; 8(37):61901-61916. PubMed ID: 28977913
[TBL] [Abstract][Full Text] [Related]
22. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
[TBL] [Abstract][Full Text] [Related]
23. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
Sigmond J; Backus HH; Wouters D; Temmink OH; Jansen G; Peters GJ
Biochem Pharmacol; 2003 Aug; 66(3):431-8. PubMed ID: 12907242
[TBL] [Abstract][Full Text] [Related]
24. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
[TBL] [Abstract][Full Text] [Related]
25. Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer.
Tanino R; Tsubata Y; Harashima N; Harada M; Isobe T
Oncotarget; 2018 Mar; 9(24):16807-16821. PubMed ID: 29682186
[TBL] [Abstract][Full Text] [Related]
26. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
[TBL] [Abstract][Full Text] [Related]
27. Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma.
Yang M; Fan WF; Pu XL; Liu FY; Meng LJ; Wang J
Oncol Lett; 2014 Jan; 7(1):227-232. PubMed ID: 24348854
[TBL] [Abstract][Full Text] [Related]
28. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
Chen X; Yang Y; Berger I; Khalid U; Patel A; Cai J; Farwell MD; Langer C; Aggarwal C; Albelda SM; Katz SI
Oncotarget; 2017 Apr; 8(15):24213-24223. PubMed ID: 27655645
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of long non-coding RNA linc-ITGB1 inhibits cancer stemness and epithelial-mesenchymal transition by reducing the expression of Snail in non-small cell lung cancer.
Guo L; Sun C; Xu S; Xu Y; Dong Q; Zhang L; Li W; Wang X; Ying G; Guo F
Thorac Cancer; 2019 Feb; 10(2):128-136. PubMed ID: 30485693
[TBL] [Abstract][Full Text] [Related]
30. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
31. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R
J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151
[TBL] [Abstract][Full Text] [Related]
32. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
[TBL] [Abstract][Full Text] [Related]
34. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
M JR; S V
Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of Napsin A resensitizes drug-resistant lung cancer A549 cells to gefitinib by inhibiting EMT.
Zhou L; Lv X; Yang J; Zhu Y; Wang Z; Xu T
Oncol Lett; 2018 Aug; 16(2):2533-2538. PubMed ID: 30008942
[TBL] [Abstract][Full Text] [Related]
36. Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells.
Han X; Chen L; Hu Z; Chen L; Sun P; Wang Y; Liu Y
J Proteomics; 2021 Apr; 237():104122. PubMed ID: 33561557
[TBL] [Abstract][Full Text] [Related]
37. Pemetrexed combination therapy in the treatment of non-small cell lung cancer.
Rosell R; Crinó L
Semin Oncol; 2002 Apr; 29(2 Suppl 5):23-9. PubMed ID: 12023789
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
Giovannetti E; Honeywell R; Hanauske AR; Tekle C; Kuenen B; Sigmond J; Giaccone G; Peters GJ
Curr Drug Targets; 2010 Jan; 11(1):12-28. PubMed ID: 19839931
[TBL] [Abstract][Full Text] [Related]
39. Establishment and Characterization of Pemetrexed-resistant NCI-H460/PMT Cells.
Xu YL; Jiang XM; Zhang LL; Chen X; Huang ZJ; Lu JJ
Anticancer Agents Med Chem; 2019; 19(6):731-739. PubMed ID: 30848214
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
